Indeed, in the CheckMate 012, CheckMate153 and KEYNOTE-001 clinical trials a lower response rate was reported in patients with EGFR or anaplastic lymphoma kinase (ALK) positive NSCLC than in those with epidermal growth factor receptor (EGFR) negative and ALK negative NSCLC [84,85,86,87]). The gene discussed is ALK; the disease is non-small cell lung carcinoma.